Cullinan, Taiho say zipalertinib plus chemo lifts median PFS by 6 months in Phase 3 REZILIENT3 trial

• Cullinan Therapeutics announced interim Phase 3 REZILIENT3 results for zipalertinib with platinum chemotherapy in first-line EGFR exon 20 insertion NSCLC.
• Data were already presented at the IASLC 2026 World Conference on Lung Cancer in Seoul.
• Trial met its main goal, showing meaningfully longer disease control versus chemotherapy alone, supporting a potential shift in first-line treatment.
• Early survival follow-up trended in favor of the zipalertinib regimen, with continued monitoring underway.
• Safety looked broadly consistent with known profiles, with more severe side effects mainly tied to manageable blood-related toxicities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260913390932) on September 13, 2026, and is solely responsible for the information contained therein.